Division of Cardiovascular Medicine, Augusta University, Augusta, GA, USA.
Department of Internal Medicine, Sinai Hospital of Baltimore, MD, USA.
Am J Med Sci. 2024 Jun;367(6):363-374. doi: 10.1016/j.amjms.2024.02.011. Epub 2024 Feb 28.
Patients with COVID-19 have been reported to experience adverse cardiovascular outcomes, such as myocarditis, acute myocardial infarction, and heart failure. Among these complications, heart failure (HF) has emerged as the most common critical complication during exacerbations of COVID-19, potentially leading to increased mortality rates and poorer clinical outcomes. We aimed to investigate the in-hospital outcomes of COVID-19 patients with HF.
We analyzed the Nationwide Inpatient Sample (NIS) dataset to select COVID-19 patients aged over 18 years who were hospitalized between January 1, 2020, and December 31, 2020, using ICD-10. Based on the presence of acute HF, the patients were divided into two cohorts. The clinical outcomes and complications were assessed at index admissions using STATA v.17."
1,666,960 COVID-19 patients were hospitalized in 2020, of which 156,755 (9.4%) had associated HF. COVID-19 patients with HF had a mean age of (72.38 ± 13.50) years compared to (62.3 ± 17.67) years for patients without HF. The HF patients had a higher prevalence of hypertension, hyperlipidemia, type 2 diabetes, smoking, and preexisting cardiovascular disease. Additionally, after adjusting for baseline demographics and comorbidities, COVID-19 patients with HF had higher rates of in-hospital mortality (23.86% vs. 17.63%, p<0.001), acute MI (18.83% vs. 10.91%, p<0.001), acute stroke (0.78% vs. 0.58%, p=0.004), cardiogenic shock (2.56% vs. 0.69%, p<0.001), and sudden cardiac arrest (5.54% vs. 3.41%, p<0.001) compared to those without HF.
COVID-19 patients admitted with acute HF had worse clinical outcomes, such as higher mortality, myocardial infarction, cardiogenic shock, cardiac arrest, and a higher length of stay and healthcare than patients without HF.
有报道称,COVID-19 患者出现不良心血管结局,如心肌炎、急性心肌梗死和心力衰竭。在这些并发症中,心力衰竭(HF)已成为 COVID-19 恶化时最常见的危急并发症,可能导致死亡率增加和临床结局较差。我们旨在研究 COVID-19 合并 HF 患者的住院结局。
我们分析了全国住院患者样本(NIS)数据集,使用 ICD-10 选择 2020 年 1 月 1 日至 12 月 31 日期间年龄超过 18 岁的 COVID-19 住院患者。根据急性 HF 的存在,将患者分为两组。使用 STATA v.17 在指数入院时评估临床结局和并发症。
2020 年共收治 1666960 例 COVID-19 患者,其中 156755 例(9.4%)合并 HF。HF 患者的平均年龄(72.38 ± 13.50)岁,无 HF 患者的平均年龄(62.3 ± 17.67)岁。HF 患者高血压、高血脂、2 型糖尿病、吸烟和既往心血管疾病的患病率更高。此外,在校正基线人口统计学和合并症后,HF 患者的住院死亡率(23.86%比 17.63%,p<0.001)、急性心肌梗死(18.83%比 10.91%,p<0.001)、急性卒中等并发症发生率更高(0.78%比 0.58%,p=0.004)、心源性休克(2.56%比 0.69%,p<0.001)和心搏骤停(5.54%比 3.41%,p<0.001)高于无 HF 患者。
与无 HF 患者相比,因急性 HF 入院的 COVID-19 患者的临床结局更差,如死亡率更高、心肌梗死、心源性休克、心脏骤停以及住院时间和医疗保健费用更高。